Article

New Point-of-Care App, PulmaCalc PPO, Predicted Post-operative Pulmonary Function Calculator

Brought to you by the UC Davis Section of General Thoracic Surgery: PulmaCalc PPO is a predicted post-operative pulmonary function calculator

Brought to you by the UC Davis Section of General Thoracic Surgery: PulmaCalc PPO is a predicted post-operative pulmonary function calculator. This unique point of care app, is ideal for health care providers, trainees and patients interested in patient centered medicine to easily calculate predicted post-operative (PPO) pulmonary function based on known pulmonary function test (PFT) values and knowledge of the extent of anatomic lung tissue removed.

The easy to use, intuitive interface allows the user to determine the PPO pulmonary function after segmentectomy, lobectomy or pneumonectomy, using known values for Forced Expiratory Volume in 1 second (FEV1) and Diffusing Capacity of the Lung for Carbon Monoxide (DLCO).

For segmentectomy and lobectomy, the user may utilize the anatomic graphic feature or the slide bar to input the number of anatomic segments removed for calculation.

For pneumonectomy a slide bar for the fraction of lung perfusion measured by quantitative radionuclide ventilation/perfusion (V/Q) scan can be used to determine PPO FEV1and DLCO.

Additional tabs describe the role for calculating PPO pulmonary function and the evidence-based medicine behind it.

This application is for informational purposes only and is not intended as a substitute for medical care, advice or professional services.

Available for the iPhone and iPad

To download PulmaCalc PPO click here:

https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewSoftware?id=670782795&mt=8

To trouble shoot or additional questions contact:

scott@fouraxisapps.com

PulmaCalc in iTunes
Related Videos
Steven H. Lin, MD, PhD
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.